Fedora Pharmaceuticals Inc. Demonstrates that FPI-1465 Increases Activity of Certain Antibiotics Against Drug-Resistant Bacteria

Published: Sep 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EDMONTON, Alberta, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. and its collaborators presented results of preclinical studies demonstrating that FPI-1465 increases the activity of beta-lactam antibiotics against bacteria that have developed resistance through the production of beta-lactamase enzymes. Beta-lactamases destroy the molecular structure of beta-lactam antibiotics, eliminating their antimicrobial activity. FPI-1465 is a beta-lactamase inhibitor (BLI) being investigated as an adjunct to antibiotics for the treatment of patients with difficult-to-treat bacterial infections.

Help employers find you! Check out all the jobs and post your resume.

Back to news